CompanyCANFNYSERamat Gan, L3

Can-Fite BioPharma

Can-Fite BioPharma develops small molecule drugs targeting oncological, inflammatory, and metabolic diseases.

SEC EDGAR ClinicalTrials.gov canfite.com

DSep 10Latest SEC filing

Sep 10Latest story

September 2026

Can-Fite BioPharma discloses $8.3 million warrant offering in SEC Form D filing

Sep 10FinancingCan-Fite BioPharma

Can-Fite sees longer survival in blinded Phase III liver cancer study, may move up interim look

Sep 2Clinical readoutCan-Fite BioPharma

August 2026

Can-Fite reports preclinical data on namodenoson-gemcitabine combination in pancreatic cancer

Aug 17Clinical readoutCan-Fite BioPharma gemcitabine

Can-Fite recaps FDA, EMA regulatory status for two Phase III drugs

Aug 12Regulatory milestoneCan-Fite BioPharma

Can-Fite submits Phase 2 protocol testing Piclidenoson in Lowe syndrome

Aug 3Clinical readoutCan-Fite BioPharma

July 2026

Can-Fite says Phase 2a pancreatic cancer data accepted for ESMO Congress 2026

Jul 20Clinical readoutCan-Fite BioPharma

Can-Fite reports two updates: psoriasis enrollment milestone and pancreatic cancer safety data

Jul 6Clinical readoutCan-Fite BioPharma